Comparative analysis of efficacy and safety of different regimens in the treatment of AIDS-related Burkitt lymphoma: a single-center retrospective study

doi:10.3969/j.issn.1006-7795.2025.03.005

Abstract

Abstract: Objective To evaluate the efficacy and safety of the dose-adjusted etoposide, doxorubicin and cyclophosphamide with vincristine, prednisone and rituximab without radiotherapy (DA-EPOCH-R) regimen versus the modified cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate (CODOX-M/IVAC-R) regimen in the treatment of patients with acquired immune deficiency syndrome (AIDS)-related Burkitt lymphoma (BL). Methods This single-center retrospective cohort study included 41 patients diagnosed with AIDS-related BL at Beijing Ditan Hospital, Capital Medical University, from December 2010 to June 2022. Among them, 26 patients received the DA-EPOCH-R regimen (observation group), and 15 patients received the modified CODOX-M/IVAC-R regimen (control group). Clinical characteristics, laboratory findings, toxicities, and treatment outcomes were analyzed. Prognostic risk factors were assessed using a multivariate Cox proportional hazards model. Results Of the 41 enrolled patients, 97.6% were male, with a median age of 43 years. The baseline median CD4+ cell count was below 200 cells/ μL in 41.5% of patients. After a median follow-up of 17 months, the complete response (CR) rate was significantly higher in the observation group compared to the control group (57.7% vs 33.3%). The median overall survival (OS) was also significantly prolonged in the observation group (18.0 months) versus the control group (6.7 months, 95% CI: 5.0－16.6) (P<0.001). Treatment-related mortality was notably lower in the observation group (0% vs. 26.7%, P<0.01). Conclusion Compared to the modified CODOX-M/IVAC-R regimen, the DA-EPOCH-R regimen demonstrates superior survival benefits and enhanced safety in the treatment of AIDS-related BL, suggesting it as the preferred chemotherapy option for this patient population.

Key words: Burkitt lymphoma, acquired immune deficiency syndrome, DA-EPOCH-R regimen, modified CODOX-M/IVAC-R regimen, efficacy and safety

CLC Number:

R512.91，R733.4

Wang Qinglian, Teng Ying, Qiao Wenying, Chen Jinglong, Ding Xiaoyan. Comparative analysis of efficacy and safety of different regimens in the treatment of AIDS-related Burkitt lymphoma: a single-center retrospective study[J]. Journal of Capital Medical University, 2025, 46(3): 427-435.

References

［1］Clark E, Royse K E, Dong Y Q, et al. Stable incidence and poor survival for HIV-related Burkitt lymphoma among the US veteran population during the antiretroviral era［J］. J Acquir Immune Defic Syndr, 2020, 84(1): 18－25.
［2］Atallah-Yunes S A, Murphy D J, Noy A. HIV-associated Burkitt lymphoma［J］. Lancet Haematol, 2020, 7(8): e594-e600.
［3］Shen Y, Zhang R F, Liu L, et al. Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin's lymphoma in Chinese population［J］. Infect Agent Cancer, 2017, 12: 7.
［4］Gibson T M, Morton L M, Shiels M S, et al. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study［J］. AIDS, 2014, 28(15): 2313－2318.
［5］Evens A M, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers［J］. Blood, 2021, 137(3): 374－386.
［6］Davi F, Delecluse H J, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group［J］. J Clin Oncol, 1998, 16(12): 3788－3795.
［7］Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma［J］. N Engl J Med, 2013, 369(20): 1915－1925.
［8］Roschewski M, Dunleavy K, Abramson J S, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma［J］. J Clin Oncol, 2020, 38(22): 2519－2529.
［9］Silva W F D, Garibaldi P M M, Rosa L I D, et al. Outcomes of HIV-associated Burkitt lymphoma in Brazil: high treatment toxicity and refractoriness rates － a multicenter cohort study［J］. Leuk Res, 2020, 89: 106287.
［10］Xiao J, Du S X, Dai G R, et al. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: an observational study［J］. Sci Rep, 2017, 7(1): 1905.
［11］Mead G M, Sydes M R, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study［J］. Ann Oncol, 2002, 13(8): 1264－1274.
［12］Noy A, Lee J Y, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma［J］. Blood, 2015, 126(2): 160－166.
［13］Barnes J A, Lacasce A S, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis［J］. Ann Oncol, 2011, 22(8): 1859－1864.
［14］Alwan F, He A N, Montoto S, et al. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy［J］. AIDS, 2015, 29(8): 903－910.
［15］Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma［J］. AIDS, 2010, 24(6): 851－856.
［16］Grimm K E, O'Malley D P. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues［J］. Ann Diagn Pathol, 2019, 38: 6－10.
［17］Zelenetz A D, Gordon L I, Abramson J S, et al. NCCN guidelines insights: B-cell lymphomas, version 6.2023.［J］ J Natl Compr Canc Netw，2023，21(11)：1118－1131.
［18］Oosten L E M, Chamuleau M E D, Thielen F W, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens［J］. Ann Hematol, 2018, 97(2): 255－266.
［19］World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach［M］. Geneva: World Health Organization, 2010.
［20］Cheson B D, Pfistner B, Juweid M E, et al. Revised response criteria for malignant lymphoma［J］. J Clin Oncol, 2007, 25(5): 579－586.
［21］NCI. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 ［EB/OL］. ［2010－06－14］. http://ctep.cancer.gov/forms/CTCAE v4.0 pdf.
［22］Oriol A, Ribera J M, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients［J］. Cancer, 2008, 113(1): 117－125.
［23］ Tao P F, Qian C, Zhou Q W, et al. Efficacy and safety of different chemotherapy regimens combined with thalidomide in the treatment of diagnosed HIV-associated diffuse large B-cell lymphoma［J］. Leuk Res Rep, 2024, 21: 100450.
［24］ Rezahosseini O, Hanaei S, Hamadani M, et al. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma［J］. Int Rev Immunol, 2018, 37(3): 165－173.
［25］ Liu Y, Xie X, Li J, et al. Immune characteristics and immunotherapy of HIV-associated lymphoma［J］. Curr Issues Mol Biol, 2024, 46(9): 9984－9997.
［26］Olszewski A J, Jakobsen L H, Collins G P, et al. Burkitt Lymphoma international prognostic index［J］. J Clin Oncol, 2021, 39(10): 1129－1138.

[1]	Wang Kaili, Chen Shizhang. Risk assessment and management of human immunodeficiency virus (HIV) patients with teeth extraction perioperative period [J]. Journal of Capital Medical University, 2019, 40(5): 754-757.
[2]	Li Ruili, Mi Haifeng, Li Hongjun, Ren Meiji, Zhao Jing, Yuan Da, Wang Wei. Diffusion tensor imaging in brain white matter of AIDS patients with normal appearance on conventional MRI by using tract-based spatial statistics [J]. Journal of Capital Medical University, 2016, 37(4): 454-459.
[3]	Huang Shujing, Chen Ming, Dai Fangfang, Yu Yanhua, Ding Xiurong, Feng Xia, Lou Jinli, Li Hongjun. Common clinical manifestations of AIDS complicated with Pneumocystis pneumonia and the diagnostic value of a plasma 1.3-β-D-glucan test [J]. Journal of Capital Medical University, 2016, 37(4): 504-508.
[4]	Liu Meiling. Spatial clustering analysis of acquired immune deficiency syndrome(AIDS)epidemic in China of 2013 [J]. Journal of Capital Medical University, 2016, 37(3): 360-363.
[5]	Tian Fei, Wang Yuanyuan, Ma Yunfang, Wang Jing, Kong Lingkun. Investigation of two intervention models to men who have sex with men in Dongcheng District, Beijing [J]. Journal of Capital Medical University, 2016, 37(2): 233-237.
[6]	Cai Juan, Zhang Qiang, Xiao Jiang, Yang Fangyu, Li Chunmei, Zhang Hongyu. The perioperative protection in HIV/AIDS patients with fracture in China: a systematic review [J]. Journal of Capital Medical University, 2015, 36(4): 654-658.
[7]	Liu Yuanzhi, Chen Binggang, Ding Wei, Qiao Luxin, Zhao Qingxia, Wu Hao, Chen Dexi, Zhang Yulin. High levels of divergent HIV-1 quasispecies in neurological opportunistic infections in China [J]. Journal of Capital Medical University, 2014, 35(1): 81-86.
[8]	Zhang Zhili, Chen Binggang, Jiang Taiyi, Qiao Luxin, Wu Hao, Chen Dexi, Zhang Yulin. Neurotoxicity of HIV-1 envelope protein gp120 V3 loop [J]. Journal of Capital Medical University, 2014, 35(1): 87-91.
[9]	Li Zhen, Wu Hao, Zhang Tong. Analysis of T cell activation in early HIV-infected individuals from MSM population [J]. Journal of Capital Medical University, 2014, 35(1): 92-95.
[10]	Xu Yuanlong, Yang Xiansan, Liu Kaiyan, Yi Yin, Li Qunhui, Huang Xiaojie, Guo Caiping, Wu Hao. Prevalence of and associated factors for HIV and HBV infections among men who have sex with men in Beijing, China [J]. Journal of Capital Medical University, 2014, 35(1): 96-100.
[11]	Tian Yaru, Jiao Yanmei, Zhang Tong, Wu Hao. Recent progress in the gene therapies against HIV-1 [J]. Journal of Capital Medical University, 2014, 35(1): 101-107.
[12]	JIAO Yanmei, HUA We, TIAN Yakun, LI Juan, JI Yunxia, WANG Ru, CHEN De, WU Hao, ZHANG Tong . Relationship between CD4⁺ CD25⁺ Foxp3⁺ Regulatory T Cells and Immune Activation in AIDS Patients Undergoing Early Highly Active Anti-retroviral Therapy [J]. Journal of Capital Medical University, 2010, 31(6): 701-705.
[13]	WANG Feng, WANG Wen-kui. Studies on the Innovation of TCM Five-organs Theory and Its Treatment of AIDS [J]. Journal of Capital Medical University, 2010, 31(6): 719-725.
[14]	SHI Ying, LIU Ning, JI Yun-xia, WEI Zheng, ZHANG Tong, CHEN De-xi, LOU Jin-li. Relationship between CCR5 Receptor Expression Levels of CD4⁺T Lymphocytes in Peripheral Blood and HIV Infection [J]. Journal of Capital Medical University, 2010, 31(6): 711-714.
[15]	WANG Peng-fei, JIAO Yan-mei, ZHU Huan-zhang, WU Hao. Progress in the Treatment of HIV/AIDS [J]. Journal of Capital Medical University, 2010, 31(6): 715-718.